{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:54:26Z","timestamp":1776920066106,"version":"3.51.2"},"reference-count":29,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"HUYA Bioscience International"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>HBI-8000 (tucidinostat) is a novel, oral histone deacetylase inhibitor that selectivity inhibits Class I (histone deacetylase 1, 2, 3) and Class II (histone deacetylase 10) with direct anti-tumor activity through various mechanisms of action, including epigenetic reprogramming and immunomodulation. It has been approved in China for the treatment of relapsed or refractory peripheral T-cell lymphoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This multicenter, prospective phase I dose-escalation trial evaluating the safety of twice weekly HBI-8000 was conducted in Japan. Eligible patients had non-Hodgkin\u2019s lymphoma and no available standard therapy. The primary endpoint was maximum tolerated dose; secondary endpoints included anti-tumor activity, safety and pharmacokinetics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fourteen patients were enrolled in the study. Twelve patients were assessed for dose-limiting toxicity: six patients in the 30\u00a0mg BIW cohort had no dose-limiting toxicitys; two of six patients in the 40\u00a0mg BIW cohort had asymptomatic dose-limiting toxicitys. Treatment was well tolerated; adverse events were predominantly mild to moderate hematologic toxicities and were managed with dose modification and supportive care. Thirteen patients were included in the efficacy analysis. Objective response was seen in five of seven patients in the 40\u00a0mg BIW cohort; three partial responders had adult T-cell leukemia-lymphoma. In the 30\u00a0mg BIW cohort, three of six patients had stable disease after the first cycle.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Treatment with HBI-8000 30\u00a0and 40\u00a0mg BIW were well-tolerated and safe, with hematological toxicities as expected from other studies of histone deacetylase inhibitor. The maximum tolerated dose and recommended dosage for phase II studies of HBI-8000 is 40\u00a0mg BIW. Preliminary efficacy results are encouraging.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyac086","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T11:09:18Z","timestamp":1652094558000},"source":"Crossref","is-referenced-by-count":6,"title":["Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin\u2019s lymphoma: phase I safety and efficacy"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5935-0385","authenticated-orcid":false,"given":"Makoto","family":"Yoshimitsu","sequence":"first","affiliation":[{"name":"Department of Hematology and Rheumatology, Kagoshima University Hospital , Kagoshima , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Tokai University School of Medicine , Isehara , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Hospital , Nagoya , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagasaki Medical Center , Omura , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilseung","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Kyushu Cancer Center , Fukuoka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Hidaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Kumamoto Medical Center , Kumamoto , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Takamatsu","sequence":"additional","affiliation":[{"name":"Medical Oncology\/Hematology\/Infectious Diseases, Fukuoka University Hospital , Fukuoka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireille","family":"Gillings","sequence":"additional","affiliation":[{"name":"HUYABIO International, LLC , San Diego , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria T","family":"Lee","sequence":"additional","affiliation":[{"name":"HUYABIO International, LLC , San Diego , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Onogi","sequence":"additional","affiliation":[{"name":"Huya Japan G.K. , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"2022060122165062600_ref1","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1158\/1078-0432.CCR-13-2088","article-title":"New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer","volume":"20","author":"Forde","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022060122165062600_ref2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"2022060122165062600_ref3","first-page":"769","article-title":"Expression profile of class I histone deacetylases in human cancer tissues","volume":"18","author":"Nakagawa","year":"2007","journal-title":"Oncol Rep"},{"key":"2022060122165062600_ref4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/1471-2407-8-381","article-title":"Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer","volume":"8","author":"Fritzsche","year":"2008","journal-title":"BMC Cancer"},{"key":"2022060122165062600_ref5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.bjc.6604199","article-title":"Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy","volume":"98","author":"Weichert","year":"2008","journal-title":"Br J Cancer"},{"key":"2022060122165062600_ref6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2008.10.047","article-title":"HDAC expression and clinical prognosis in human malignancies","volume":"280","author":"Weichert","year":"2009","journal-title":"Cancer Lett"},{"key":"2022060122165062600_ref7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrg2485","article-title":"The many roles of histone deacetylases in development and physiology: implications for disease and therapy","volume":"10","author":"Haberland","year":"2009","journal-title":"Nat Rev Genet"},{"key":"2022060122165062600_ref8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.molcel.2008.02.030","article-title":"Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control","volume":"30","author":"Bhaskara","year":"2008","journal-title":"Mol Cell"},{"key":"2022060122165062600_ref9","doi-asserted-by":"crossref","first-page":"eabf4148","DOI":"10.1126\/sciadv.abf4148","article-title":"An unexpected role for p53 in regulating cancer cell\u2013intrinsic PD-1 by acetylation","volume":"7","author":"Cao","year":"2021","journal-title":"Sci Adv"},{"key":"2022060122165062600_ref10","doi-asserted-by":"crossref","first-page":"757","DOI":"10.7150\/ijbs.9067","article-title":"Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications","volume":"10","author":"Li","year":"2014","journal-title":"Int J Biol Sci"},{"key":"2022060122165062600_ref11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.hoc.2012.01.006","article-title":"Role of histone deacetylase inhibitors in the treatment of lymphomas and multiple myeloma","volume":"26","author":"Zain","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"key":"2022060122165062600_ref12","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1182\/blood-2002-11-3387","article-title":"Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma","volume":"101","author":"Pasqualucci","year":"2003","journal-title":"Blood"},{"key":"2022060122165062600_ref13","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1128\/MCB.25.5.1608-1619.2005","article-title":"Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas","volume":"25","author":"Duan","year":"2005","journal-title":"Mol Cell Biol"},{"key":"2022060122165062600_ref14","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity","volume":"69","author":"Ning","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022060122165062600_ref15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.5582\/irdr.2016.01024","article-title":"Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China","volume":"5","author":"Lu","year":"2016","journal-title":"Intractable Rare Dis Res"},{"key":"2022060122165062600_ref16","doi-asserted-by":"crossref","first-page":"16083","DOI":"10.18632\/aging.103536","article-title":"Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia","volume":"12","author":"Kong","year":"2020","journal-title":"Aging"},{"key":"2022060122165062600_ref17","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an International Workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"2022060122165062600_ref18","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2008.18.2428","article-title":"Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia lymphoma: a proposal from an international consensus meeting","volume":"27","author":"Tsukasaki","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022060122165062600_ref19","volume-title":"Practice Guideline for Hematopoietic Organ Tumor (version 2013)","author":"Japanese Society of Hematology [Internet]"},{"key":"2022060122165062600_ref20","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060122165062600_ref21","author":"MedDRA [Internet]"},{"key":"2022060122165062600_ref22","author":"Common Terminology Criteria for Adverse Events (CTCAE)"},{"key":"2022060122165062600_ref23","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s12185-017-2286-1","article-title":"Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I\/II and pharmacokinetics study","volume":"106","author":"Maruyama","year":"2017","journal-title":"Int J Hematol"},{"key":"2022060122165062600_ref24","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjh.12819","article-title":"A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma","volume":"165","author":"Ogura","year":"2014","journal-title":"Br J Haematol"},{"key":"2022060122165062600_ref25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejphar.2007.06.015","article-title":"Mechanisms of HDAC inhibitor-induced thrombocytopenia","volume":"571","author":"Matsuoka","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"2022060122165062600_ref26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/toxsci\/kfw104","article-title":"Histone deacetylase inhibitors prolong cardiac repolarization through transcriptional mechanisms","volume":"153","author":"Stan","year":"2016","journal-title":"Toxicol Sci"},{"key":"2022060122165062600_ref27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4161\/epi.3.3.6253","article-title":"A work in progress: the clinical development of histone deacetylase inhibitors","volume":"3","author":"Marsoni","year":"2008","journal-title":"Epigenetics"},{"key":"2022060122165062600_ref28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral T-cell lymphoma: a multicenter real-world study in China","volume":"10","author":"Shi","year":"2017","journal-title":"J Hematol Oncol"},{"key":"2022060122165062600_ref29","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyac086\/43922639\/hyac086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyac086\/43922639\/hyac086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T22:17:58Z","timestamp":1654121878000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article\/doi\/10.1093\/jjco\/hyac086\/6596992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":29,"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyac086","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]},"article-number":"hyac086"}}